These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9660347)

  • 1. SEC going after insider trading based on medical research results. Securities Exchange Commission.
    Skolnick AA
    JAMA; 1998 Jul; 280(1):10-1. PubMed ID: 9660347
    [No Abstract]   [Full Text] [Related]  

  • 2. SEC slaps another researcher for insider trading. Securities and Exchange Commission.
    Skolnick AA
    JAMA; 1998 Jul; 280(2):124. PubMed ID: 9669773
    [No Abstract]   [Full Text] [Related]  

  • 3. New SEC regulations could hinder biotech investment. US Securities and Exchange Commission.
    Bouchie A
    Nat Biotechnol; 2002 Jul; 20(7):639-40. PubMed ID: 12089533
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomedical research and insider trading.
    Ferguson JR
    N Engl J Med; 1997 Aug; 337(9):631-4. PubMed ID: 9271488
    [No Abstract]   [Full Text] [Related]  

  • 5. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
    Whitener MD
    Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 7. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 8. In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare.
    Ben-Asher D; Juris M
    J Leg Med; 2000 Sep; 21(3):271-349. PubMed ID: 11055154
    [No Abstract]   [Full Text] [Related]  

  • 9. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 10. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 11. AstraZeneca must pay €52.5m fine for anticompetitive tactics, rules European court.
    Hawkes N
    BMJ; 2012 Dec; 345():e8396. PubMed ID: 23230222
    [No Abstract]   [Full Text] [Related]  

  • 12. Hoechst plans divestitures to gain FTC nod.
    Scott L
    Mod Healthc; 1995 Sep; 25(39):32. PubMed ID: 10151416
    [No Abstract]   [Full Text] [Related]  

  • 13. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wall Street and clinical trials.
    Steinbrook R
    N Engl J Med; 2005 Sep; 353(11):1091-3. PubMed ID: 16162879
    [No Abstract]   [Full Text] [Related]  

  • 15. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
    Steinhauer EH
    Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
    [No Abstract]   [Full Text] [Related]  

  • 16. Bundling patented drugs and medical services: an antitrust analysis.
    Hurwitz MA
    Spec Law Dig Health Care Law; 1992 Jan; (155):7-39. PubMed ID: 10115664
    [No Abstract]   [Full Text] [Related]  

  • 17. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacies take uniform price demands to court.
    Moskowitz DB
    J Am Health Policy; 1994; 4(4):24-7. PubMed ID: 10136676
    [No Abstract]   [Full Text] [Related]  

  • 19. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 20. Will antitrust cops bust billion-dollar drug deals?
    Barnett AA
    J Am Health Care; 1994; 4(5):5-7. PubMed ID: 10142816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.